Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Poynard

Showing results (171-180 of 222) with videos related to

Pageof 23
Sort By:
JHEP Reports : Innovation in Hepatology|June 18, 2021
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCVThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
BMC Gastroenterology|October 17, 2007
Meta-analyses of FibroTest diagnostic value in chronic liver diseaseThierry Poynard, Rachel Morra, Philippe Halfon, et al.
Gastroenterology|October 31, 2002
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infectionLaurent Alric, Vincent Di-Martino, Janik Selves, et al.
Gastro Hep Advances|August 12, 2024
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis BThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 3, 2014
Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplantsRaluca Pais, Pascal Lebray, Geraldine Rousseau, et al.
European Journal of Gastroenterology & Hepatology|December 3, 2019
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetesThierry Poynard, Valentina Peta, Olivier Deckmyn, et al.
Comparative Hepatology|January 23, 2003
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver diseasePhilippe Halfon, Françoise Imbert-Bismut, Djamila Messous, et al.
BMC Gastroenterology|April 24, 2010
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)Thierry Poynard, Pascal Lebray, Patrick Ingiliz, et al.
Journal of Hepatology|May 29, 2013
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis CThierry Poynard, Joseph Moussalli, Mona Munteanu, et al.
Journal of Hepatology|November 20, 2012
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized studyThierry Poynard, Jordi Bruix, Eugene R Schiff, et al.
Pageof 23

Showing results (171-180 of 222) with videos related to

Sort By:
Pageof 23
JHEP Reports : Innovation in Hepatology|June 18, 2021
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCVThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
BMC Gastroenterology|October 17, 2007
Meta-analyses of FibroTest diagnostic value in chronic liver diseaseThierry Poynard, Rachel Morra, Philippe Halfon, et al.
Gastroenterology|October 31, 2002
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infectionLaurent Alric, Vincent Di-Martino, Janik Selves, et al.
Gastro Hep Advances|August 12, 2024
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis BThierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 3, 2014
Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplantsRaluca Pais, Pascal Lebray, Geraldine Rousseau, et al.
European Journal of Gastroenterology & Hepatology|December 3, 2019
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetesThierry Poynard, Valentina Peta, Olivier Deckmyn, et al.
Comparative Hepatology|January 23, 2003
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver diseasePhilippe Halfon, Françoise Imbert-Bismut, Djamila Messous, et al.
BMC Gastroenterology|April 24, 2010
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)Thierry Poynard, Pascal Lebray, Patrick Ingiliz, et al.
Journal of Hepatology|May 29, 2013
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis CThierry Poynard, Joseph Moussalli, Mona Munteanu, et al.
Journal of Hepatology|November 20, 2012
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized studyThierry Poynard, Jordi Bruix, Eugene R Schiff, et al.
Pageof 23